医学
药品审批
临床试验
重症监护医学
药理学
药品
内科学
作者
Jeremy Puthumana,Joshua D. Wallach,Joseph S. Ross
出处
期刊:JAMA
[American Medical Association]
日期:2018-07-17
卷期号:320 (3): 301-301
被引量:53
标识
DOI:10.1001/jama.2018.7619
摘要
This study used the Drugs@FDA database to review FDA-approved “breakthrough” therapies from 2012 to 2017 (characterizing the pivotal clinical trials that serve as the basis of FDA approval), and premarket development and review times to assess the strength of evidence supporting breakthrough approvals.
科研通智能强力驱动
Strongly Powered by AbleSci AI